Pharmaceutical News

RSS

Study reveals no evidence of link between bisphosphonates to esophageal cancer risk

Although some reports have suggested a link between the use of oral bisphosphonates (drugs that prevent the loss of bone mass) and esophageal cancer, analysis of medical data from more than 80,000 patients in the United Kingdom found that use of these drugs was not significantly associated with new cases of esophageal or gastric cancer, according to a study in the August 11 issue of JAMA.

11 Aug 2010

CADTH Review Panel releases recommendations for Biologic Response Modifier Agents for Adults with RA

The Canadian Agency for Drugs and Technologies in Health's (CADTH) Therapeutic Review Panel released last week their recommendations for Biologic Response Modifier Agents for Adults with Rheumatoid Arthritis (RA).

10 Aug 2010

FDA grants Orphan Drug Designation to YM BioSciences' JAK1/2 inhibitor

YM BioSciences Inc., announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration has granted Orphan Drug Designation to the Company's highly-selective JAK1/2 inhibitor, CYT387, for the treatment of myelofibrosis, a chronic debilitating unmet medical need, in which a patient's bone marrow is replaced by scar tissue, and for which treatment options are limited or unsatisfactory.

10 Aug 2010

Weifang Shengtai to supply Kelun with 10,000 tons of dextrose monohydrate injection grade

Shengtai Pharmaceutical, Inc. announced on August 6, 2010 that Weifang Shengtai Pharmaceutical Co., Ltd ("Weifang Shengtai"), its operating subsidiary in China, entered into an agreement with Kelun Pharmaceutical ("Kelun") to supply Kelun with 10 thousand tons of dextrose monohydrate injection grade: Kelun Guizhou will be supplied with 7 hundred tons and Kelun Sichuan with 9.3 thousand tons. The agreement is entered into at reasonable prices and will be carried out by prepayments.

10 Aug 2010

Transcept Pharmaceuticals second-quarter net loss decreases to $2.06 million

Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced financial results for the three and six months ended June 30, 2010.

10 Aug 2010

Unigene second-quarter revenue decreases to $3.03 million

Unigene Laboratories, Inc. has reported its financial results for the quarter ended June 30, 2010.

10 Aug 2010

Systemic lupus erythematosus drug market to quadruple from $400 million in 2009 to over $1.6 billion in 2019

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven primarily by the launch and uptake of Human Genome Sciences/GlaxoSmithKline's Benlysta, the systemic lupus erythematosus (SLE) drug market will quadruple from about $400 million in 2009 to more than $1.6 billion in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

10 Aug 2010

Anika second-quarter product revenue increases 56% to $13.7 million

Anika Therapeutics, Inc., a leader in products for tissue protection, healing, and repair, based on hyaluronic acid technology, today reported financial results for the quarter ended June 30, 2010.

10 Aug 2010

Endo to acquire Penwest for $5.00 per share

Endo Pharmaceuticals today announced actions designed to advance the company's leadership and growth in pain management, including an agreement to acquire all outstanding shares of Penwest Pharmaceuticals for $5.00 in cash per share, or an estimated enterprise value of approximately $144 million at the time of deal close. Penwest has been working with Endo since 1997 on the development and commercialization of OPANA® ER and receives a royalty stream on net sales of the product.

10 Aug 2010

Psoriasis drug market to double from $3.4 billion in 2009 to $6.8 billion in 2019: Pharmacor 2010

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the continued uptake of marketed and emerging interleukin and TNF-alpha inhibitors and a twofold increase in the penetration of biologics in the moderate-to-severe population will drive the psoriasis drug market to double from $3.4 billion in 2009 to $6.8 billion in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

10 Aug 2010

FDA approves Pfizer's Prefilled Dual-Chamber Syringe for XYNTHA administration in hemophilia A patients

Pfizer Inc. announced today that the U.S. Food and Drug Administration has granted approval of the use of a Prefilled Dual-Chamber Syringe for administration of XYNTHA® Antihemophilic Factor (Recombinant) Plasma/Albumin-Free to hemophilia A patients. XYNTHA is a recombinant factor VIII product indicated for both the control and prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia) and for surgical prophylaxis in patients with hemophilia A.

9 Aug 2010

Progenics second-quarter total revenue decreases to $2.3 million

Progenics Pharmaceuticals, Inc. today announced its results of operations for the second quarter and six months ended June 30, 2010.

9 Aug 2010

FDA accepts Salix's XIFAXAN550 sNDA for Priority Review

Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Company's efficacy supplement to the New Drug Application (NDA) for XIFAXAN® (rifaximin) 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome (Non-C IBS) and IBS-related bloating.

9 Aug 2010

Dr Reddy’s launches first generic darbepoetin alfa

Dr. Reddy's Laboratories Ltd. announced today the launch of Cresp® - the first generic darbepoetin alfa in the world, and the only darbepoetin alfa in India. Cresp® has been approved in India for the treatment of anemia due to chronic kidney disease and anemia due to chemotherapy.

9 Aug 2010

Health Canada approves first targeted biological therapy to show survival benefit in stomach cancer

Roche announced today that after priority review, Health Canada has approved HERCEPTIN(R) (trastuzumab), in combination with XELODA(R) (capecitabine) or intravenous 5-fluorouracil and cisplatin, for the first-line treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach (gastric cancer) or gastro-esophageal cancer.

9 Aug 2010

Clinical Data first-quarter gross revenue increases 52% to $6.2 million

Clinical Data, Inc. today announced operational and financial results for the first quarter ended June 30, 2010, noting key accomplishments including the acceptance of the Company's new drug application (NDA) for vilazodone by the U.S. Food and Drug Administration (FDA) and the successful completion of a public offering .

9 Aug 2010

AOBO to launch Yin Yang balancing medication Pai Du Qing Zhi Tablet

American Oriental Bioengineering, Inc., a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products, today announced that its Boke brand Pai Du Qing Zhi Tablet, a prescription medicine aimed at achieving the balance of Yin Yang by regulating metabolism, in order to cleanse the blood and detoxify, dispose of hemorrhoids, fight obesity and lower hyperlipemia, will be commercially launched in the third quarter of 2010.

9 Aug 2010

AOBO announces commercial launch of osteoporosis drug Yi Shen Jian Gu Gel

American Oriental Bioengineering, Inc., a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products, today announced the commercial launch of Boke brand Yi Shen Jian Gu Gel ("YSJG" Gel) after successful test marketing in the second quarter of 2010.

9 Aug 2010

Repros Therapeutics receives positive feedback from FDA for Androxal

Repros Therapeutics Inc. today announced that the Company has received positive written feedback from the FDA (the "Agency") regarding the Company's drug candidate Androxal. The Agency concurred with Repros' indication statement for the use of Androxal in the treatment of secondary hypogonadism in men wishing to preserve fertility.

9 Aug 2010

An overview of SRVP annual meeting

Islamic countries have acknowledged the importance of self-reliance in vaccine production and are committed to establishing closer cooperation towards achieving it, as they ended their 6th Annual Meeting of Self-Reliance in Vaccine Production (SRVP), in Bandung, Indonesia.

9 Aug 2010

Pharmaceutical News

Study reveals no evidence of link between bisphosphonates to esophageal cancer risk

CADTH Review Panel releases recommendations for Biologic Response Modifier Agents for Adults with RA

FDA grants Orphan Drug Designation to YM BioSciences' JAK1/2 inhibitor

Weifang Shengtai to supply Kelun with 10,000 tons of dextrose monohydrate injection grade

Transcept Pharmaceuticals second-quarter net loss decreases to $2.06 million

Unigene second-quarter revenue decreases to $3.03 million

Systemic lupus erythematosus drug market to quadruple from $400 million in 2009 to over $1.6 billion in 2019

Anika second-quarter product revenue increases 56% to $13.7 million

Endo to acquire Penwest for $5.00 per share

Psoriasis drug market to double from $3.4 billion in 2009 to $6.8 billion in 2019: Pharmacor 2010

FDA approves Pfizer's Prefilled Dual-Chamber Syringe for XYNTHA administration in hemophilia A patients

Progenics second-quarter total revenue decreases to $2.3 million

FDA accepts Salix's XIFAXAN550 sNDA for Priority Review

Dr Reddy’s launches first generic darbepoetin alfa

Health Canada approves first targeted biological therapy to show survival benefit in stomach cancer

Clinical Data first-quarter gross revenue increases 52% to $6.2 million

AOBO to launch Yin Yang balancing medication Pai Du Qing Zhi Tablet

AOBO announces commercial launch of osteoporosis drug Yi Shen Jian Gu Gel

Repros Therapeutics receives positive feedback from FDA for Androxal

An overview of SRVP annual meeting

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News